Article Text

Download PDFPDF
Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?
  1. Algirdas Markauskas, MD*,
  2. Ole Mogensen, MD, DMSci*,
  3. René dePont Christensen, PhD and
  4. Pernille Tine Jensen, MD, PhD*
  1. *Department of Gynaecology & Obstetrics, Odense University Hospital; and
  2. Research Unit of General Practice, University of Southern Denmark, Odense, Denmark.
  1. Address correspondence and reprint requests to Algirdas Markauskas, MD, Department of Gynaecology & Obstetrics, Odense University Hospital, Sdr Boulevard 29, 5000 Odense C, Denmark. E-mail: Algirdas.Markauskas{at}rsyd.dk.

Abstract

Objective The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer.

Materials and Methods We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer.

Results Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (≤1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months.

Conclusions We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.

  • Debulking surgery
  • Epithelial ovarian cancer
  • Surgical complexity
  • Postoperative morbidity
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.